Roivant Sciences Ltd. (ROIV) insider trading

By person

21 insiders · 297 transactions

929×

Matthew Gline holds 929 times base salary in stock. $673.89M of shares against $725.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Gline last reported holding, valued at $40.45, the price Common Shares was last bought or sold at on the open market here, on 15 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Gold Daniel Allen

Director

—

$341.57M (36)

−$341.57M

22,654,981

3.14%

$916.39M

−82.9%

QVT Financial LP entity

Director by Deputization

—

$300.69M (32)

−$300.69M

13,689,166

1.90%

$553.73M

−88.6%

MANCHESTER KEITH S

Director

—

$258.62M (30)

−$258.62M

15,442,623

2.14%

$624.65M

−81.0%

SVF Investments (UK) Ltd entity

10% owner

—

$242.63M (3)

−$242.63M

73,031,667

10.11%

$2.95B

−26.5%

Ramaswamy Vivek

10% owner

—

$224.96M (17)

−$224.96M

47,011,612

6.51%

$1.90B

−21.5%

Venker Eric

President & Immunovant CEO

—

$200.44M (90) scheduled

−$200.44M

1,599,154

0.2214%

$64.69M

+15.1%

Sumitomo Chemical Co., Ltd. entity

10% owner

—

$130.00M (1)

−$130.00M

71,251,083

9.86%

$2.88B

−17.5%

VIKING GLOBAL INVESTORS LP entity

10% owner

—

$128.70M (4)

−$128.70M

12,884,307

1.78%

$521.17M

−50.2%

VIKING GLOBAL PERFORMANCE LLC entity

10% owner

—

$128.70M (4)

−$128.70M

12,884,307

1.78%

$521.17M

−50.2%

Sukhatme Mayukh

President & CIO

—

$124.75M (17) scheduled

−$124.75M

18,630,739

2.58%

$753.61M

+515.9%

Torti Frank

President and Vant Chair

—

$82.04M (3) scheduled

−$82.04M

13,536,202

1.87%

$547.54M

—

Gline Matthew

CEO

$49.96K (1)

$71.78M (16) scheduled

−$71.73M

16,659,945

2.31%

$673.89M

+890.7%

Dexcel Pharma Technologies Ltd. entity

10% owner

$20.15M (3)

—

+$20.15M

102,849,443

14.24%

$4.16B

+4.1%

Kumar Rakhi

Chief Accounting Officer

—

$9.87M (25) scheduled

−$9.87M

162,306

0.0225%

$6.57M

−38.8%

Pulik Richard

CFO

—

$9.14M (3) scheduled

−$9.14M

271,810

0.0376%

$10.99M

+16.1%

Fitzgerald Meghan

Director

—

$3.27M (5) scheduled

−$3.27M

41,162

0.0057%

$1.67M

—

Epperly Melissa B,

Director

—

$2.01M (5)

−$2.01M

14,954

0.0021%

$604.89K

—

Humes Jennifer

Chief Accounting Officer

—

$384.07K (1)

−$384.07K

109,782

0.0152%

$4.44M

—

Oren Ilan

Director

—

123,680

0.0171%

$5.00M

—

MOMTAZEE JAMES C

Director

—

111,959

0.0155%

$4.53M

—

Lo Andrew

Director

—

52,142

0.0072%

$2.11M

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Fitzgerald Meghan

15 Sep 2026

Director

Sold on a plan

400

$40.45

$16.18K

Fitzgerald Meghan

15 Sep 2026

Director

Sold on a plan

4,712

$39.68

$186.97K

Epperly Melissa B,

15 Sep 2026

Director

Sold on a plan

600

$40.38

$24.23K

Epperly Melissa B,

15 Sep 2026

Director

Sold on a plan

4,338

$39.65

$172.00K

Venker Eric

23 Sep 2025

President & Immunovant CEO

Sold on a plan

611,000

$14.83

$9.06M

Venker Eric

4 Oct 2023

Chief Operating Officer

Sold on a plan

153,027

$10.11

$1.55M

Showing 250 of 297 transactions. The figures above use every one of them.

Roivant Sciences Ltd.

By person

Individual transactions

What was left out